Biological agents against TNFα have been developed for the treatment of inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis [13,14,15,16]. Here, TNF is linked to inflammatory bowel disease.